PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-6.83
Both companies show losses. Martin Whitman would check if industry conditions create special situations.
2398.57
P/S of 2398.57 while GNPX has no sales. Bruce Berkowitz would examine revenue quality advantage.
4.11
P/B 1.25-1.5x GNPX's 3.13. Martin Whitman would scrutinize if premium reflects better growth prospects.
-35.08
Both companies show negative FCF. Martin Whitman would check for industry-wide capital intensity issues.
-35.16
Both companies show negative operating cash flow. Martin Whitman would check for industry-wide operational issues.
4.11
Fair value ratio 1.25-1.5x GNPX's 3.13. Martin Whitman would scrutinize if premium reflects better prospects.
-3.66%
Both companies show losses. Martin Whitman would check for industry-wide issues.
-2.85%
Both companies show negative FCF. Martin Whitman would check for industry-wide capital intensity issues.